Story

Ben & Jerry's Foundation Faces Shutdown After Magnum Cuts Funding

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Ben & Jerry's Foundation Faces Shutdown After Magnum Cuts Funding

Summary

The philanthropic arm of the ice cream maker may suspend operations by year-end after its parent company, Magnum, cut its funding and evicted it from its offices, prompting a legal battle.

Text size
Background

The Ben & Jerry’s Foundation announced on Wednesday that it will likely suspend operations at the end of the year unless it secures a favorable court ruling in its dispute with parent company Magnum Ice Cream. The move comes after Magnum cut the foundation's funding and ordered it to vacate its corporate offices.

Funding Cut Sparks Legal Challenge

According to a press release from the foundation, Magnum terminated its funding in April 2025 and set a deadline of July 15, 2026, for the eviction. The foundation's ability to continue its philanthropic work now depends on the outcome of a legal challenge it has filed in New York federal court, which is expected to extend into next year.

Dispute Centers on Audit Findings

Sample IUX Markets – In-articleAd

The conflict appears to stem from a Unilever-backed audit from December 2025, which the source material said found “deficiencies in financial controls and governance” at the foundation. The Ben & Jerry’s Foundation stated that it disputes the audit's conclusions, highlighting that previous audits had not raised similar concerns.

Context for Investors

This dispute adds a new layer of complexity to the relationship between the socially-conscious brand and its corporate parent. Magnum was spun off from Unilever in December with a valuation of approximately €7.8 billion. The source material noted that Magnum's handling of the Ben & Jerry's brand has already drawn criticism from some investors.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST